HAHale Akpınar

Hale Akpınar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hale Akpınar has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Effectiveness of Vedolizumab and Ustekinumab in Biologic-Experienced Ulcerative Colitis: A Real-World Multicenter Study from the Güntürk Group

    by Filiz Araz, Orhan Sezgin, Sezgin Barutçu, Nalan Gülşen Ünal, Göksel Bengi, Burak Özşeker, Ümit Karaoğullarindan, Gözde Derviş Hakim, Birol Özer, Hale Akpinar, et al.

    Background/Aims: The study aimed to compare the effectiveness and safety of vedolizumab (VDZ) and ustekinumab (UST) in patients with ulcerative colitis (UC) previously exposed to biologic therapy and to determine whether prior biologic exposure affects treatment outcomes. Materials and Methods: In this multicenter retrospective study, data from 420 patients treated at 14 centers with VDZ (n = 260) or UST (n = 160) between 2020 and 2024 were analyzed. Outcomes included steroid-free clinical remission (SFCR), clinical remission (CR), treatment persistence, and adverse events at weeks 14-16, 52, and 104. Inverse probability of treatment weighting was used to adjust for baseline differences between treatment groups. Results: In the weighted cohort, rates of SFCR and CR were comparable between treatments at weeks 14-16 and 52 (P > .05). At week 104, SFCR rates did not differ significantly between treatment groups, whereas VDZ was associated with higher CR rates (adjusted odds ratio [aOR] = 0.66; 95% CI = 0.45-0.91). In subgroup analyses, VDZ was associated with higher CR and SFCR rates among patients with 1 prior biologic exposure, whereas UST was associated with higher CR (aOR = 1.86; 95% CI = 1.10-3.16) and SFCR (aOR = 1.79; 95% CI = 1.05-3.09) rates at week 52 among patients with 2 or more prior biologic exposures. Treatment persistence was significantly higher with UST (aOR = 1.82; 95% CI = 1.36-2.44). Safety profiles were comparable between treatment groups. Conclusion: VDZ and UST demonstrated broadly comparable effectiveness in biologic-experienced UC. The higher CR rate favoring VDZ at week 104 should be interpreted cautiously given the lack of a significant difference in SFCR rate and limitations of long-term followup assessment. Exploratory subgroup findings suggest that UST may have a potential role in patients who were heavily pretreated. These findings may inform hypotheses regarding individualized treatment sequencing. Cite this article as: Araz F, Sezgin O, Barutçu S, et al. Comparative effectiveness of vedolizumab and ustekinumab in biologicexperienced ulcerative colitis: A real-world multicenter study from the GÜNTÜRK group. Turk J Gastroenterol.Published online October 5, 2026. doi: 10.5152/tjg.2026.26102.

  • Open Access

    Modified Glasgow Prognostic Score as a dual biomarker for disease activity and malnutrition in inflammatory bowel disease

    by Aysen Aytin Karzan, Çağdaş Erdoğan, Hale Akpınar

    The modified Glasgow Prognostic Score (mGPS) combines C-reactive protein and albumin levels to assess systemic inflammation and nutritional status. We evaluated mGPS as a combined marker associated with disease activity and malnutrition in inflammatory bowel disease (IBD) patients. This cross-sectional study included 286 IBD patients (175 Crohn’s disease, 109 ulcerative colitis) from a tertiary referral center. Disease activity was assessed using validated clinical indices. Nutritional status was evaluated using 7-point Subjective Global Assessment (SGA). mGPS was calculated as: 0 (CRP < 10 mg/L), 1 (CRP ≥ 10 mg/L, albumin ≥ 3.5 g/dL), or 2 (CRP ≥ 10 mg/L, albumin < 3.5 g/dL). Receiver operating characteristic analysis compared the discriminative performance of mGPS versus individual biomarkers. Overall, 73.8% of patients had mGPS 0, 18.9% had mGPS 1, and 7.3% had mGPS 2. A strong association existed between mGPS and disease activity (p < 0.001), with 80% of mGPS 2 patients having active disease compared to 21% of mGPS 0 patients. Similarly, mGPS was strongly associated with malnutrition (p < 0.001), with 6-fold higher prevalence in mGPS 2 versus mGPS 0 patients (33.3% vs. 5.2%). mGPS demonstrated incrementally higher discriminative performance compared to individual biomarkers for both disease activity (AUC 0.73 vs. 0.66 for CRP alone) and malnutrition (AUC 0.71 vs. 0.64 for CRP alone). In multivariable analysis, mGPS 2 was independently associated with active disease (OR 12.84, 95% CI 3.89–42.37) and malnutrition (OR 7.89, 95% CI 2.65–23.52). mGPS is strongly associated with both disease activity and malnutrition and demonstrates good discriminative performance for identifying patients at higher risk.

  • Open Access

    Neutrophil-Lymphocyte Ratio and LDH/Albumin Ratio as Biomarkers for Severity and Mortality in Acute Pancreatitis

    by Göksel Bengi, İbRahim Çelik, Süleyman Dolu, Soner Önem, Müjde Soytürk, Serkan Rendeci, Ömer Topalak, Hale Akpinar

    Background/Aims: Acute pancreatitis (AP) is a common and potentially severe condition, and early identification of its severity is critical for appropriate clinical management. This study aimed to investigate the role of the Neutrophil-Lymphocyte Ratio (NLR) and Lactate dehydrogenase (LDH)/Albumin Ratio (LAR) in predicting the severity and prognosis of patients with AP and to determine the optimal NLR value. Materials and Methods: The demographic, clinical, and laboratory data of patients diagnosed with AP were retrospectively analyzed. Neutrophil-Lymphocyte Ratio was measured at admission (0 hours), and at 24 and 48 hours; C-reactive protein (CRP) values were recorded at 0 and 48 hours; and the LAR was calculated based on LDH and albumin values measured at 48 hours post admission. These values were compared with disease severity, mortality, organ failure, length of hospital stay, and the need for intensive care according to Ranson and bedside index of severity in AP (BISAP) scores. Results: According to the BISAP scoring, 38 patients (16%) were classified as having severe AP, while 200 patients (84%) had mild AP. The best parameter for predicting severe AP was found to be the 24-hour NLR with a sensitivity of 79% and specificity of 67%. The best parameter for predicting mortality and organ failure was the NLR at 48 hours. There was a statistically significant difference between the length of hospital stay and the need for intensive care with the CRP value at 48 hours. Additionally, there was a statistically signifi cant relationship between LAR and mortality, length of hospital stay, organ failure, and the need for intensive care. Conclusion: This study demonstrates that the NLR and the LDH/Albumin Ratio are important and easily accessible markers for determining the severity and prognosis of AP. The NLR at 48 hours is an effective parameter for predicting mortality and organ failure, while the LDH/Albumin Ratio is significant in predicting mortality. Cite this article as: Bengi G, Çelik İ, Dolu S, et al. Neutrophil-lymphocyte ratio and LDH/albumin ratio as biomarkers for severity and mortality in acute pancreatitis. Turk J Gastroenterol. 2025;36(8):497-507.


  • Open Access

    Clinical Features and Prevalence of Osteosarcopenia in Chronic Pancreatitis

    by Hüseyin Döngelli, Göksel Bengi, Raif Can Yarol, Canan Altay, Süleyman Dolu, Nilay Danış, Ömer Selahattin Topalak, Hale Akpınar, Servet Kızıldağ, Müjde Soytürk

    Background/Aims: The prevalence of sarcopenia and osteopenia/osteoporosis is increased in chronic pancreatitis (CP). This study aims to evaluate the prevalence and related factors of osteosarcopenia in CP patients. Materials and Methods: Eighty-three CP patients were included in this cross-sectional observational study. Sarcopenia was assessed by measuring the surface area of the paravertebral muscles at the third lumbar region. Pancreatic fecal elastase (PFE) tests evaluated exocrine pancreatic insufficiency (EPI), while dual-energy x-ray absorptiometry scans assessed osteopenia/osteoporosis. EORTC PAN26 and a symptom questionnaire were administered, alongside nutritional marker assessments concurrent with PFE. Results: The prevalence of sarcopenia and osteopenia/osteoporosis was found to be 22.9% (n = 19) and 68.7% (n = 44), respectively. Factors associated with sarcopenia included male gender (OR: 4.9, P = .044), severe EPI (OR: 4.2, P = .043), smoking (OR: 4.6, P = .040), and zinc deficiency (OR: 2.2, P = .029). Severe EPI was significantly associated with osteopenia/osteoporosis (P = .010), diabetes mellitus (P = .001), sarcopenia (P = .016), and zinc deficiency (P = .012). Individuals with osteoporosis had higher PAN26 scores (P = .029). Factors independently associated with osteopenia/osteoporosis included female gender (OR: 7.8, P = .004), severe EPI (OR: 8.1, P = .003), and sarcopenia (OR: 5, P = .037). The prevalence of osteosarcopenia was 19.2%. Conclusion: Osteosarcopenia is common in CP patients. Smoking, zinc deficiency, EPI, and male gender are strongly associated with sarcopenia. Screening for osteosarcopenia is essential in CP patients to facilitate appropriate interventions. Cite this article as: Döngelli H, Bengi G, Yarol RC, et al. Clinical features and prevalence of osteosarcopenia in chronic pancreatitis. Turk J Gastroenterol. 2025;36(10):669-679.


  • Open Access

    HER2 Status in Gastric and Gastroesophageal Carcinomas: Evaluation of Histopathological Fingings, Paired Resection Biopsy Specimens, and the Effect of Neoadjuvant Therapy: A Single Center Study*

    by Resmiye Irmak Yuzuguldu, Ozgul Sagol, Mehtat Unlu, Merve Keskinkilic, Serhan Derici, Hale Akpinar, Sulen Sarioglu

    Background/Aims: Accurately determining the human epidermal growth factor receptor 2 (HER2) status is crucial in identifying suitable candidates for targeted therapy in gastric cancer, considering the cost and potential side effects of anti-HER2 treatments. This study aimed to assess HER2 overexpression/amplification prevalence in gastric and gastroesophageal cancer patients, its correlation with clinicopathological characteristics, and the consistency of HER2 status between biopsy and radical specimens. Materials and Methods: We analyzed data from 667 specimens of 600 gastric/gastroesophageal cancer patients at Dokuz Eylül University Faculty of Medicine from 2012 to 2021. The correlation of HER2 expression and amplification status and clinicopathological parameters were assessed. Furthermore, we compared HER2 status concordance between paired biopsy-radical specimens when both endoscopic and radical materials were present. Additionally, we compared HER2 status before and after treatment in patients receiving neoadjuvant chemotherapy. Results: In our study, +3 HER2 immunohistochemistry results were more common in gastroesophageal junction tumors (23%). Human epidermal growth factor receptor 2 immunohistochemistry positivity and HER2 gene amplification were found to be significantly more common in males, people over 65 years of age, and intestinal morphology. Overall concordance of HER2 status between radical and biopsy materials was 95.5%. Conclusion: The high HER2 concordance between the paired biopsy and radical samples holds significant importance in clinical management. This finding is particularly noteworthy since the HER2 assessment can generally be conducted on small/limited biopsy materi als in routine practice. Our study is the most extensive series from Türkiye and the Balkans, which will shed light on our country’s data by investigating the relationship of HER2 with clinicopathological parameters in gastric/gastroesophageal carcinomas. Cite this article as: Yuzuguldu RI, Sagol O, Unlu M, et al. HER2 status in gastric and gastroesophageal carcinomas: evaluation of histopathological findings, paired resection biopsy specimens, and the effect of neoadjuvant therapy: A single center study. Turk J Gastroenterol. 2025;36(6):357-370.

  • Open Access

    Does Helicobacter pylori infection affect indirect hepatic fibrosis tests?

    by Ali Cagatay Bozkina, Goksel Bengi, Suleyman Dolu, Anil Aysal, Mujde Soyturk, Ender Berat Ellidokuz, Omer Selahattin Topalak, Hale Akpınar, Mesut Akarsu

    Background and Aim: Early detection, accurate evaluation, and proper follow-up of fibrosis in chronic liver disease are crucial for improving disease prognosis. Indirect biochemical fibrosis tests, such as the AST-to-Platelet Ratio Index (APRI) and Fibrosis-4 (FIB-4) score, have been developed, incorporating parameters like AST, ALT, and platelet count. However, the influence of factors such as Helicobacter pylori (H. pylori) on fibrosis tests such as APRI and FIB-4 remains unclear, and this study aimed to evaluate its impact. Materials and Methods: This study included 190 patients (aged ≥18 years) who underwent gastric and liver biopsies at a tertiary center between 2006 and 2021. Patients were categorized into three groups based on liver histo-pathological findings: mild (F0-1), moderate (F2-3), and advanced (F4-6) fibrosis. Additionally, patients were grouped based on H. pylori presence as determined by gastric histopathology. Demographic, clinical, laboratory, imaging, and histopathological characteristics were analyzed and compared between groups. Results: Among the 190 patients, H. pylori was detected in 135 (71%) and was absent in 55 (29%). No significant differences were observed between H. pylori-positive and -negative groups in terms of AST, ALT, platelet count, INR, FIB-4, or APRI scores. For APRI, significant differences were found between mild-moderate and mild-advanced fibrosis groups (p0.05). For FIB-4, significant differences were observed across all fibrosis groups (p

  • İNFLAMATUVAR BARSAK HASTALARINDA YAŞAM KALİTESİ DEĞERLENDİRME ANKETİ

    by Can Akçura, Hale Akpınar, Göksel Bengi, Pembe Keskinoğlu

    Giriş ve Amaç Crohn hastalığı ve ülseratif kolit olmak üzere iki ana gruba ayrılan inflamatuvar barsak hastalığı (İBH), hastaların yaşam kalitesini etkileyen kronik inflamatuvar bir hastalıktır. Tanımlayıcı ve metodolojik olan bu araştırmada, 1992 yılında yayınlanan ve farklı ülkelerde geçerliliği olan İnflamatuvar Barsak Hastalığı Yaşam Kalitesi Değerlendirme Anketi'nin (İBH-YKA) Türk toplumu için geçerlilik ve güvenilirliğinin açıklanması amaçlanmaktadır. Gereç ve Yöntemler Araştırmaya Dokuz Eylül Üniversitesi İnflamatuvar Barsak Hastalıkları kliniğine Mart 2013-Mayıs 2013 tarihleri arasında başvuran bilişsel fonksiyonları yerinde olan, okuryazar ve çalışmaya katılmaya istekli 176 yetişkin hasta dahil edildi. Güvenilirliği hesaplamak için anket, seçilen 30 hastaya ikinci kez uygulandı. İBH-YKA 36 sorudan oluşmaktadır ve faktör analizi yapısı beş boyuttan oluşmaktadır; "Sistemik semptomlar", "Barsak semptomları", "Fonksiyonel yetersizlik", "Sosyal yetersizlik" ve "Emosyonel fonksiyon". Anketin kapsam geçerliliği bir uzman görüşü ile test edilmiştir. Güvenilirlik değerlendirmesi, iç tutarlılık ve madde-toplam korelasyonu ile yapılmıştır. Bulgular Cronbach-alfa katsayısı 0.951, tüm madde-toplam korelasyon değerleri p < 0.05 ve rho değerleri > 0.50 olmak üzere anlamlı bulundu. Yapı geçerliliğini test etmek için uygulanan faktör analizine göre sorular dört faktör altında toplanmış ve bu faktör yapısı ile toplam varyansın %62.77'si açıklanmıştır. Sonuç Sonuçlara göre İBH-YKA’nın Türk hastalar için geçerli ve güvenilir olduğu kanıtlanmış ve ölçeğin validasyonu başarıyla tamamlanmıştır. Anahtar Kelimeler: inflamatuvar barsak hastalığı, Crohn hastalığı, ülseratif kolit, yaşam kalitesi, anket


  • Open Access

    Evaluation of In Vitro Biofilm Formation of Helicobacter pylori in Different Culture Media

    by Sibel Gülseroğlu, Hale Akpınar, Özlem Yılmaz, Müjde Soytürk

    Objective: Biofilms are surface-attached cell communities that play a role in the survival of bacteria. Helicobacter pylori, a gram-negative pathogen that colonizes the human gastric mucosa, forms biofilms, causing treatment failure and the risk of developing peptic ulcers, gastritis and gastric cancer in infected individuals. The aim of the study is to evaluate the biofilm formation abilities of H. pylori ATCC 26695 and three clinical strains in different culture media. Material and Method: Biofilm formation characteristics of H. pylori strains using different culture media were evaluated, and the crystal violet (CV) staining method (measured at OD 595 ) was used. Various media were used for incubating H. pylori strains: Brucella broth (BB), TSB with 10% FBS, BHI with 10% FBS, BB with 10% FBS, BB with 10% FBS + 0.25% glucose, and BB with 10% FBS + 1% glucose (incubated for 3 days). Additionally, BB with 1% FBS, BB with 10% FBS, and BB with 5% inactivated human serum were incubated for 2 and 4 days at 37°C under microaerophilic conditions. Results: It was observed that 5% inactived human serum was more effective in biofilm formation of H. pylori ATCC 26695 and three clinical strains. However, there was no biofilm production in the strains cultured with Brucella broth alone and that the strains cultured with TSB + 10% FBS could not form a strong biofilm compared to other media. Conclusion: Different culture media used for H. pylori ATCC 26695 and three clinical strains affect biofilm formation. It is thought that in vitro experiments to prevent biofilm formation may provide a solution to the prevention of H. pylori infection.


  • Open Access

    The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients

    by Sinakhanım Huseynzada, Tuba Yüce İnEl, Farid Hajiyev, Aydan Köken Avşar, Ali Balcı, Hale Akpınar, Fatoş Önen, İsmail Sarı

    Objective: Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect, systemic immunosuppression is not expected, and this may have a negative effect on the extra-intestinal symptoms of inflammatory bowel disease, particularly spondyloarthritis. Currently, there is limited data regarding the effect of vedolizumab on spondyloarthritis symptoms. We aimed to investigate whether vedolizumab has an effect on the occurrence of rheumatological symptoms and the clinical course of patients who have spondyloarthritis. Methods: Thirty-nine adult inflammatory bowel disease patients who were followed up in the Gastroenterology Clinic and treated with vedolizumab were included in the study. Patients were reviewed in terms of rheumatological manifestations. The occurrence of new musculoskeletal findings during the vedolizumab treatment was recorded. Patients with a former diagnosis of spondyloarthritis were evaluated for the activity of axial and peripheral manifestations during the vedolizumab. Results: There were 39 inflammatory bowel disease patients (29 Crohn’s disease, 10 ulcerative colitis, 48.7% (n = 19) male) who had been treated with vedolizumab. The mean age of the patients was 41.4 ± 15.7 years, and the duration of inflammatory bowel disease was 10.4 ± 7.5 years. A total of 17 (44%) patients had accompanying spondyloarthritis findings (mean age 47.08 ± 15.325 years and 58.8% M). Seven patients had axial dominant symptoms and 6 of them were in an active disease state before vedolizumab. During vedolizumab, all but 1 continued to be active. There were 14 patients with arthritis/arthralgias before vedolizumab and only 3 had improvement with therapy. On the other hand, there were 3 patients who had new-onset arthralgias/arthritis with vedolizumab. In total, 6 patients needed to stop vedolizumab because of spondyloarthritis activation (n = 2) and uncontrolled inflammatory bowel disease (n = 4), respectively. Conclusion: Treatment with vedolizumab seems no effect on both the occurrence and the course of rheumatological manifestations in inflammatory bowel disease patients. Further studies are required to replicate our results. Cite this article as: Huseynzada S, Yüce Inel T, Hajiyev F, et al. The effect of vedolizumab on spondyloarthritis symptoms in a cohort of inflammatory bowel disease patients. Eur J Rheumatol 2023;10(2):50-56.


  • Open Access

    Liver Mass Caused by Fasciola Hepatica: A Case Report

    by Öykü Ünsal, Elif Kurtuluş, Hatice Bi̇ni̇ci̇er, Canan Altay, Hale Akpinar

    Bu olgu sunumunda, fasciola hepatica’nın nonspesifik semptomlarla gelebileceğini; karaciğer kitlesi ile başvuran bir hastada ayırıcı tanıda paraziter enfeksiyonların akılda tutulması gerektiğini; laboratuvar bulguları, seroloji ve görüntüleme yöntemlerinin tanıda değerli olduğunu vurgulamayı amaçladık. Komorbidi olmayan 33 yaşında kadın hasta dış merkezden tarafımıza karaciğerde kitle nedeniyle yönlendirildi. Hastanın ana yakınmaları halsizlik, yorgunluk ve künt vasıfta karın ağrısı olup fizik muayenesi olağandı. Laboratuvar tetkiklerinde anemi ve eozinofili saptandı. Fasciola hepatica serolojisi pozitif olarak saptandı. Abdomen manyetik rezonans görüntülemede;T1 ağırlıklı yağ baskılı sekansta karaciğerde izlenen lezyonda paraziter hastalığın oluşturduğu intraparankimal tünelleri temsil eden tubuler yapıda mikrokistik lezyon izlendi. Hepatobilier konseyde Fasciola hepatica olarak değerlendirilen hastaya triklabendazol tedavisi verildi. Sonuç olarak; eozinofili ile birlikte karaciğer kitlesi ile başvuran hastalarda, ayırıcı tanıda paraziter enfeksiyonlar akılda bulundurulmalıdır. Laboratuvar bulguları, seroloji ve görüntüleme yöntemleri tanıda değerlidir.